By
Drug Target Review2024-08-13T14:30:51
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-17T12:40:00Z
2026-06-17T09:14:00Z
2023-11-20T13:43:43
Sponsored by Merck
2026-06-15T11:00:00
Sponsored by Miltenyi Biotec
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2024-01-09T09:30:19
Sponsored by Sartorius
2023-09-27T13:56:39
Sponsored by Euretos
2025-04-22T14:58:00
Sponsored by Takara Bio USA
Site powered by Webvision Cloud